Zacks Investment Research Downgrades Sartorius (SARTF) to Sell

Zacks Investment Research downgraded shares of Sartorius (OTCMKTS:SARTF) from a hold rating to a sell rating in a report issued on Tuesday.

According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “

Shares of OTCMKTS SARTF opened at $109.50 on Tuesday. The company has a current ratio of 1.62, a quick ratio of 1.00 and a debt-to-equity ratio of 1.08. Sartorius has a 1-year low of $109.50 and a 1-year high of $149.00.

Sartorius (OTCMKTS:SARTF) last issued its quarterly earnings results on Tuesday, October 23rd. The company reported $0.79 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.05. Sartorius had a return on equity of 20.21% and a net margin of 9.09%. The company had revenue of $459.56 million for the quarter, compared to the consensus estimate of $460.00 million. Sell-side analysts expect that Sartorius will post 2.95 earnings per share for the current year.

About Sartorius

There is no company description available for Sartorius AG.

Featured Article: What are different types of coverage ratios?

Get a free copy of the Zacks research report on Sartorius (SARTF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply